成都先导药物开发股份有限公司关于宁波聚智先导生物科技合伙企业（有限合伙）增持公司股份计划的公告

Core Viewpoint - Ningbo Juzhi Xiandao Biotechnology Partnership (Limited Partnership) plans to increase its stake in Chengdu Xiandao Pharmaceutical Development Co., Ltd. based on confidence in the company's future development and long-term investment value [2][3]. Group 1: Shareholding Structure - Juzhi Xiandao currently holds 38,651,163 shares, accounting for 9.65% of the total share capital, while the controlling shareholder Jin Li holds 81,876,948 shares, representing 20.43% of the total share capital. Together, they own 120,528,111 shares, which is 30.08% of the total share capital [2]. Group 2: Buyback Plan Details - The buyback plan will be executed within 12 months from the announcement date, with a total investment amount between RMB 25 million and RMB 50 million. The funding will come from its own funds and a special loan from Industrial Bank Co., Ltd. Chengdu Branch [3][6]. - The buyback will not set a price range for the shares and will not trigger a mandatory takeover bid or change the controlling shareholder [3][6]. Group 3: Compliance and Regulations - The buyback plan complies with relevant laws and regulations, including the Company Law of the People's Republic of China and the Securities Law of the People's Republic of China, and will adhere to the rules of the Shanghai Stock Exchange [6].